Daiichi Sankyo Company announced that Daiichi Sankyo Biotech Co, a subsidiary of Daiichi Sankyo, has made its shipment of Vaxzevria intramuscular injection, a vaccine against novel coronavirus (development code, AZD1222; hereinafter, Covid-19 vaccine) developed by AstraZeneca K.K. (hereinafter, AstraZeneca). This shipment of the Covid-19 vaccine is to be provided to Southeast Asian countries and other regions through the Japanese Government.
Under the contract manufacture agreement of the Covid-19 vaccine that Daiichi Sankyo concluded with AstraZeneca in February 2021, Daiichi Sankyo Biotech has engaged in manufacturing the Covid-19 vaccine, including vial filling and packaging, since March of the same year.
The Japanese government has announced that it will supply 30 million doses of AstraZeneca’s Covid-19 vaccine to various countries and regions through COVAX and through other means. In response to this announcement, a portion of the Covid-19 vaccine to be shipped from Daiichi Sankyo is expected to be provided to countries and regions including Southeast Asian countries through the Japanese Government.
As part of efforts towards ending the global Covid-19 pandemic, Daiichi Sankyo is striving to support regions in need of medical access through contract manufacture of the Covid-19 vaccine.
